Personalized timing-based treatments for pancreatic cancer
Development of a precision medicine platform for circadian based therapeutics in pancreatic cancer
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · NIH-10908362
This project grows mini-tumors from small biopsies to find personalized drug choices and the best time-of-day to give them for people with pancreatic cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10908362 on ClinicalTrials.gov |
What this research studies
If you have pancreatic ductal adenocarcinoma, doctors would use routine endoscopic biopsy tissue to grow patient-derived organoids (mini-tumors) in the lab. Researchers will test different chemotherapy and targeted drugs on those organoids and examine how drug effects change with circadian (time-of-day) conditions. The team will combine molecular profiling and drug-response data to build a precision platform that links tumor biology and timing to treatment choices. Results aim to guide more personalized treatment plans based on each patient’s tumor behavior.
Who could benefit from this research
Good fit: Adults diagnosed with pancreatic ductal adenocarcinoma who can provide tissue via routine endoscopic biopsy and receive care at or near the study center are the ideal candidates.
Not a fit: Patients who cannot provide biopsy tissue, have very rapidly progressing disease that prevents organoid creation, or have cancers other than pancreatic ductal adenocarcinoma are unlikely to benefit from this work.
Why it matters
Potential benefit: If successful, this could help doctors choose drugs and the best timing to give them, potentially improving effectiveness and reducing side effects for pancreatic cancer patients.
How similar studies have performed: Patient-derived organoids have previously predicted clinical drug responses in other settings, while applying circadian-timed therapies to pancreatic cancer is a newer and less-tested approach.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BISHEHSARI, FARAZ — UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- Study coordinator: BISHEHSARI, FARAZ
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancer Cause, Cancer Etiology, Cancers